Revolution or redux? Assessing IQOS through a precursor product
| Autor: | Pamela M. Ling, Lauren M. Dutra, Jesse Elias, Gideon St.Helen |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Health (social science)
Tobacco Industry Risk Assessment Tobacco industry Tobacco smoke 03 medical and health sciences 0302 clinical medicine Health claims on food labels Humans 030212 general & internal medicine Product (category theory) Health risk health care economics and organizations non-cigarette tobacco products 030505 public health Public economics Public Health Environmental and Occupational Health advertising and promotion Tobacco Products tobacco industry documents Business 0305 other medical science Tobacco product Research Paper toxicology |
| Zdroj: | Tobacco Control |
| ISSN: | 1468-3318 0964-4563 |
| DOI: | 10.1136/tobaccocontrol-2018-054327 |
| Popis: | BackgroundPhilip Morris International (PMI) currently claims that its heated tobacco product, IQOS, reduces health risk by reducing users’ exposure to harmful and potentially harmful constituents present in tobacco smoke. Given the tobacco industry’s long history of misrepresenting and obfuscating research, independent assessment of PMI’s claims is important. Analysis of Accord, a failed but strikingly similar precursor to IQOS, may help contextualise PMI’s claims in its Modified Risk Tobacco Product (MRTP) application.MethodsWe analysed previously secret internal Philip Morris (PM) and PMI documents, public communications and MRTP application.ResultsPM marketed Accord as a ‘cleaner’ tobacco product in an attempt to address smokers’ growing health concerns without making explicit health claims. While PM communications asserted that Accord reduced users’ exposure to harmful constituents, company scientists and executives consistently stressed to both regulators and the public that such reductions did not render Accord safer. IQOS’s design and marketing are similar to Accord’s. On the basis of aerosol chemistry data, IQOS reduces user exposure to some compounds compared with Accord but raises them for others.DiscussionIQOS appears to be a variant of Accord without consistent improvements in exposure to aerosol toxic compounds. In contrast to PM’s past claims for Accord, PMI now claims in its MRTP application that IQOS reduces health risk. This shift in stance is likely not the result of any toxicological difference between Accord and IQOS, but rather a change in the social and regulatory landscape permitting these claims. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|